Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Repayments of Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

GILEAD SCIENCES, INC. Repayments of Long-Term Debt

GILEAD SCIENCES, INC. (GILD) reported Repayments of Long-Term Debt of $4.75 billion for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.

Discontinued › Cash Flow › Financing Activities

us-gaap:RepaymentsOfLongTermDebt · last filed 2022-02-23

  • GILEAD SCIENCES, INC. repayments of long-term debt for the quarter ending 2021-12-31 was $1.00B.
  • GILEAD SCIENCES, INC. repayments of long-term debt for the quarter ending 2021-09-30 was $2.50B.
  • GILEAD SCIENCES, INC. repayments of long-term debt for the quarter ending 2021-06-30 was $0.00.
  • GILEAD SCIENCES, INC. repayments of long-term debt for the quarter ending 2021-03-31 was $1.25B.
  • GILEAD SCIENCES, INC. repayments of long-term debt for fiscal 2021 was $4.75B.
  • GILEAD SCIENCES, INC. repayments of long-term debt for fiscal 2011 was $649.99M.
  • GILEAD SCIENCES, INC. repayments of long-term debt for fiscal 2010 was $0.00, a 100.00% decline from fiscal 2009.
  • GILEAD SCIENCES, INC. repayments of long-term debt for fiscal 2009 was $305.45M.
Period endRepayments of Long-term Debt 3 monthRepayments of Long-term Debt 6 monthRepayments of Long-term Debt 9 monthRepayments of Long-term Debt 12 month
2021-12-31$1.00B
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23
$3.50B
derived: sum of 2 quarters · filed 2022-02-23
$3.50B
derived: sum of 3 quarters · filed 2022-02-23
$4.75B
10-K · filed 2022-02-23
2021-09-30$2.50B
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$2.50B
derived: sum of 2 quarters · filed 2021-11-03
$3.75B
10-Q · filed 2021-11-03
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$1.25B
10-Q · filed 2021-08-05
2021-03-31$1.25B
10-Q · filed 2021-05-06
2011-12-31$649.99M
10-K · filed 2012-02-23
2010-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23
$0.00
10-K · filed 2012-02-23
2010-09-30$0.00
10-Q · filed 2010-11-08
2009-12-31$49.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23
$72.00K
derived: sum of 2 quarters · filed 2012-02-23
$305.45M
10-K · filed 2012-02-23
2009-09-30$23.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08
$305.41M
10-Q · filed 2010-11-08
2009-06-30$305.38M
10-Q · filed 2010-08-09
2008-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2010-03-01
$0.00
derived: sum of 2 quarters · filed 2010-03-01
$0.00
10-K · filed 2010-03-01
2008-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05
$0.00
10-Q · filed 2009-11-05
2008-06-30$0.00
10-Q · filed 2009-08-05
2007-12-31$0.00
10-K · filed 2010-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31